Ergoteles’s Marker Therapeutics MRKR Stock Holding History

Ergoteles’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-13,740	Closed	-$383K	–	1515
2021 Q2	$383K	Buy	+13,740	New	+$362K	0.01%	936

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ergoteles's MRKR Position: Q3 2021 in Review

Ergoteles sold out of Marker Therapeutics (MRKR) in Q3 2021, closing a stake of 13,740 shares — an estimated $383K sold.

Ergoteles first reported a position in MRKR in Q2 2021 and held it in 1 quarter. The position peaked at $383K in Q2 2021. 63 funds tracked by Wall St. Rank hold MRKR as of Q3 2021.

Ergoteles reported no remaining Marker Therapeutics position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 13,740 Marker Therapeutics shares in Q3 2021, an estimated $383K.
Ergoteles first reported a position in Marker Therapeutics in Q2 2021 and held it in 1 quarter.
Ergoteles's Marker Therapeutics position peaked at $383K in Q2 2021.
63 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.